Adjuvant chemotherapy in resected lung cancer: Two-year experience in a university hospital

Canadian Respiratory Journal

Volumn 15, Issue 5, 2008, Pages 270-274

  Bouchard, Nicole ^a   Laberge, Francis ^a   Raby, Bruno ^a   Martin, Sylvie ^a,b   Lacasse, Yves ^a,b  

^a LAVAL UNIVERSITY   (Canada)

^b UNIVERSITÉ LAVAL   (Canada)

Author keywords

Adjuvant chemotherapy; Lung cancer; Referral patterns; Treatment compliance; Treatment toxicity

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; ETOPOSIDE; GEMCITABINE; NAVELBINE; PACLITAXEL;

ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; ADULT; ALOPECIA; ARTICLE; CANCER CHEMOTHERAPY; CANCER STAGING; CHEMOTHERAPY INDUCED EMESIS; CONSTIPATION; CONTROLLED STUDY; CYTOPENIA; DIARRHEA; DRUG FATALITY; DYSGEUSIA; DYSPHAGIA; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HUMAN; LUNG NON SMALL CELL CANCER; LUNG RESECTION; LUNG SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MIXED TUMOR; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; STOMATITIS; TINNITUS;

EID: 57349197897     PISSN: 11982241     EISSN: None     Source Type: Journal    
DOI: 10.1155/2008/462147     Document Type: Article

References (13)

1. Parkin DM. Global cancer statistics in the year 2000. Lancet Oncol 2001;2:533-43. (Erratum in 2001;2:596).
2. Spiro SO, Porter JC. Lung cancer - where are we today? Current advances in staging and nonsurgical treatment. Am J Respir Crit Care Med 2002;166:1166-96.
3. Mountain CF. Revisions in die International System for Staging Lung Cancer. Chest 1997;111:1710-7.
4. Spira A, Ettinger DS. Multidisciplinary management of lung cancer. N Engl J Med 2004;350:379-92.
5. Pignon JP, Tribodet H, Scagliotti GV, et al. Lung Adjuvant Cisplatin Evaluation (LACE): A pooled analysis of five randomized clinical trials including 4,584 patients. J Clin Oncol 2006;24(Suppl 18):7008. (Abst)
6. Winton T, Livingston R, Johnson D, et al. Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer. N Engl J Med 2005;352:2589-97.
7. Simon GR, Turrisi A. Management of small cell lung cancer: ACCP evidence-based clinical practice guidelines (2nd edition). Chest 2007;132(3 Suppl):324S-339S.
8. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global Strategy for Diagnosis, Management, and Prevention of COPD. (Version current at May 28, 2008).
9. Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982;5:649-55.
10. Kassam F, Shepherd FA, Johnston M, et al. Referral patterns for adjuvant chemotherapy in patients with completely resected non-small cell lung cancer. J Thorac Oncol 2007;2:39-43.
11. Lacasse Y, Bucher HC, Wong E, et al. "Incomplete resection" in non-small cell lung cancer: Need for a new definition. Canadian Lung Oncology Group. Ann Thorac Surg 1998;65:220-6.
12. Arriagada R, Bergman B, Dunant A, Le Chevalier T, Pignon JP, Vansteenkiste J. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med 2004;350:351-60.
13. Douillard JY, Rosell R, De Lena M, et al. Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): A randomised controlled trial. Lancet Oncol 2006; 7: 719-727. (Erratum in 2006;7:797).